Decisions on the use of adjuvant chemotherapy in ER positive, HER2 negative primary breast cancer are guided by the risk of distant recurrence. EndoPredict provides prognostic information from a molecular signature combined with tumor size and nodal status (EPclin Risk Score). Oncotype DX® provides prognostic information only from a molecular signature (Recurrence Score – RS).
This study validated the prognostic value of EndoPredict and compared the prognostic ability of EndoPredict with Oncotype DX®.
Fill out the form below to download your free copy of the comparison clinical summary and learn more about this key study.